Boundless Bio Inc (BOLD) Stock Price, Quote & News

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 dem...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 766 9912

Website: boundlessbio.com

Address:

10955 Alexandria Way, Suite 100, San Diego, United States

d_risk Nov. 5 at 4:18 PM

$BOLD - Boundless Bio Inc. Common Stock - 10Q - Updated Risk Factors BOLD flags major risks for 2025: urgent need for more capital, potential safety issues with ecDTx, tough choices on resource allocation, regulatory and policy disruptions, IP protection challenges, possible infringement claims, healthcare reform pressures, and global trade headwinds. #Biotechnology #HealthcareReform #IntellectualProperty #RegulatoryChallenges #CapitalRisk 🟢 Added 🟠 Removed https://d-risk.ai/BOLD/10-Q/2025-11-05

0 · Reply

Lukey63 Oct. 24 at 3:26 PM

$BOLD barely 25% of cash and TBV, 2+ year runway, in hot sector (oncology). This is due for min 100-200% rally soon. Very…

0 · Reply

Capo18 Oct. 23 at 6:08 PM

$BOLD gespannt was da kommt!

1 · Reply

Mason9999 Oct. 23 at 1:24 AM

$BOLD @AZOZ You still waiting for this one to hit?

1 · Reply

NYBomba Oct. 19 at 4:09 PM

$BOLD - results of BBI-355 will probably be presented @ 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on Oct 23rd, depending on how it's received and if it's entering phase 3, stock price can really jet upward ... all spec but the potential can be enormous ... Here's the skinny: if the outlook was bleak a PR would've been released saying so; presenting at conference is very positive. GLTA

0 · Reply

Golibajje Oct. 16 at 3:01 PM

$SPRB watch out $BOLD breakout started!!! - Trading 1/5th of cash!! - Oncogene amplifications, targeting most aggressive cancer, which has no cure!! - Multi billion $$$ market!! Catalyst: International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA https://investors.boundlessbio.com/static-files/fd938b87-a5eb-40a2-8e70-d9a62d90ed85

0 · Reply

Getthismoney101 Oct. 14 at 4:47 PM

$BOLD been holding this in my IRA since 1.05 , going to be a beauty $SPRB

0 · Reply

petemal Oct. 9 at 1:12 AM

$SPRB over valued raise coming in $BOLD looking good

1 · Reply

petemal Oct. 9 at 1:10 AM

$IVDA need some news $BOLD undervalued

0 · Reply

petemal Oct. 9 at 1:09 AM

$TDOC moving $BOLD next big mover

0 · Reply

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 13, 2025, 4:05 PM EDT - 24 days ago

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 5, 2025, 7:00 AM EDT - 3 months ago

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Jun 5, 2025, 4:58 PM EDT - 5 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 23, 2025, 4:01 PM EDT - 5 months ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

May 9, 2025, 7:00 AM EDT - 6 months ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Apr 3, 2025, 7:00 AM EDT - 7 months ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 8 months ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 26, 2025, 7:00 AM EST - 9 months ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 3, 2025, 10:00 AM EST - 9 months ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Dec 12, 2024, 4:01 PM EST - 11 months ago

Boundless Bio Announces Pipeline and Leadership Updates

Nov 25, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 7, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 13, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 6, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Mar 30, 2024, 1:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

MMA MNDR NTCL NTHI ROTR UBXG WAY

Mar 27, 2024, 6:55 PM EDT - 1 year ago

Boundless Bio Announces Pricing of Initial Public Offering

Mar 23, 2024, 12:20 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

ALAB AUNA INTJ MNDR RDDT

Mar 12, 2024, 4:16 PM EDT - 1 year ago

Boundless Bio Starts $100 Million U.S. IPO Plan

d_risk Nov. 5 at 4:18 PM

0 · Reply

Lukey63 Oct. 24 at 3:26 PM

$BOLD barely 25% of cash and TBV, 2+ year runway, in hot sector (oncology). This is due for min 100-200% rally soon. Very…

0 · Reply

Capo18 Oct. 23 at 6:08 PM

$BOLD gespannt was da kommt!

1 · Reply

Mason9999 Oct. 23 at 1:24 AM

$BOLD @AZOZ You still waiting for this one to hit?

1 · Reply

NYBomba Oct. 19 at 4:09 PM

0 · Reply

Golibajje Oct. 16 at 3:01 PM

0 · Reply

Getthismoney101 Oct. 14 at 4:47 PM

$BOLD been holding this in my IRA since 1.05 , going to be a beauty $SPRB

0 · Reply

petemal Oct. 9 at 1:12 AM

$SPRB over valued raise coming in $BOLD looking good

1 · Reply

petemal Oct. 9 at 1:10 AM

$IVDA need some news $BOLD undervalued

0 · Reply

petemal Oct. 9 at 1:09 AM

$TDOC moving $BOLD next big mover

0 · Reply

petemal Oct. 9 at 1:08 AM

$RXRX seeing double digits $BOLD under valued

0 · Reply

stick_to_stocks Oct. 4 at 9:57 AM

$BOLD there was an interesting slap a couple of days ago. Added

0 · Reply

Getthismoney101 Sep. 29 at 1:22 PM

$BOLD beaten down below cash value

0 · Reply

Getthismoney101 Sep. 29 at 1:06 PM

$BOLD LETS GO!!

0 · Reply

NVDAMillionaire Sep. 9 at 12:24 PM

$BOLD Really good write-up that perfectly summarizes BOLD's present situation. So if you want to bring your BOLD knowledge up to date or just discover BOLD, this is required reading. https://beyondspx.com/quote/BOLD/analysis/unlocking-cancer-s-code-boundless-bio-s-ecdna-strategy-and-extended-runway-bold

0 · Reply

MorenitaScorp Sep. 2 at 12:43 PM

$BOLD ⌚️

0 · Reply

topstockalerts Sep. 2 at 11:03 AM

Pre Market Top Gainers PT2 $MLYS $FLGC $BOLD $TIXT $CYCU

0 · Reply

habesha_kingtchalla Aug. 28 at 2:01 AM

$BOLD

0 · Reply

ZenithZephyr Aug. 23 at 7:50 AM

$BOLD Boundless Bio Inc is a clinical stage oncology company with novel target approach

0 · Reply

JarvisFlow Aug. 11 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Boundless Bio ( $BOLD ), setting the rating to Buy with a target price of 5 → 4.

0 · Reply

TheOrangeBall Jul. 29 at 11:08 PM

$BOLD how is this not pulling a $BHVN type run like they had a couple years ago??

0 · Reply

TheOrangeBall Jul. 23 at 11:38 PM

$BOLD now begins the steady climb up

0 · Reply

Market Cap	28.21M
Revenue (ttm)	0.00
Net Income (ttm)	-65.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	42,800
Avg Vol	126,364
Day's Range	N/A - N/A
Shares Out	22.39M
Stochastic %K	10%
Beta	-0.90
Analysts	Sell
Price Target	$3.50